Affiliation:
1. Cairo University
2. Theodor Bilharz Research Institute, Cairo, Egypt
Abstract
Abstract
Background
The problem of resistance to beta-lactam antibiotics, which is caused by ESBL and AmpC β-lactamases, is getting worse globally. Infections caused by bacterial isolates harboring these enzymes are difficult to treat with carbapenems being the sole effective treatment option for such infections. The objective of this study was to assess the sensitivity of the cefepime-tazobactam combination against ESBL- and/or AmpC-producing Gram-negative bacilli.
Methods
This is an observational cross-sectional study carried out on 100 Gram-negative bacilli. ESBL production was screened by using the disc diffusion test followed by confirmation by the combined disc confirmatory test, the screening for AmpC production was conducted using the cefoxitin disc test, which was subsequently confirmed by the AmpC disc test. Isolates confirmed positive for ESBL and/ or AmpC production were investigated for their susceptibility to antibiotics.
Results
Among 100 Gram-negative bacilli, 44 isolates were confirmed as ESBL producers by the combined disc confirmatory test out of 56 isolates that tested positive for ESBL production through the disc diffusion test. The presence of AmpC production was assessed using the cefoxitin disc test, 32 isolates were screened to be AmpC producers, and the AmpC disc test confirmed AmpC production in 9 isolates of them. Using the Mast® D68C set, 32 isolates were ESBL producers, 3 were AmpC producers, and 4 isolates were ESBL/AmpC co-producers. The highest sensitivity was to cefepime-tazobactam (91.48%) followed by the carbapenems.
Conclusion
Cefepime-tazobactam showed remarkable activity against ESBL and/or AmpC-producing Gram-negative bacilli and may be considered as a therapeutic alternative to carbapenems.
Publisher
Research Square Platform LLC
Reference49 articles.
1. Antibiotic resistance;Frieri M;J Infect Public Health,2017
2. Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications;Iredell J;BMJ,2016
3. Prevalence of Extended Spectrum Beta-lactamases and AmpC beta-lactamases in clinical isolates of gram-negative bacilli at a tertiary care hospital;Rao MJ;J Evol Med Dent,2018
4. Extended-spectrum Beta-lactamase and AmpC beta-lactamases producing Gram-negative bacilli isolated from clinical specimens at International Clinical Laboratories, Addis Ababa, Ethiopia;Tekele S;PLoS ONE,2020
5. The structure of b-lactamases;Ambler R;Philos Trans R Soc Lond B Biol Sci,1980